To Revolutionize Antibiotic Pipeline Start With Rapid Diagnostics
This article was originally published in The Gray Sheet
Point-of-care diagnostics can make antibiotic development faster, easier and cheaper, but creating them will be a bumpy ride, according to a recent discussion among government and industry officials.
You may also be interested in...
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Medtech Insight talked with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and market opportunities. See what Gadot said about the market opportunity here.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.